EXEL vs HRMY
As of Sep 20, 2026, Exelixis (EXEL) scores 6.5/10 and Harmony Biosciences Holdings (HRMY) 7.5/10 on AlphaStocks' five-model composite, so HRMY scores higher. EXEL trades 5% below its model fair value.
EXEL
EXELIXIS, INC.
6.5
Consider Buy
$58.35
HRMY
Harmony Biosciences Holdings, Inc.
7.5
Strong Buy
$42.06
EXEL vs HRMY: Which is the Better Investment?
EXELIXIS, INC. (EXEL) scores 6.5/10 while Harmony Biosciences Holdings, Inc. (HRMY) scores 7.5/10 on AlphaStocks' composite model. Harmony Biosciences Holdings, Inc. has the higher composite rating of Strong Buy. On a P/E basis, Harmony Biosciences Holdings, Inc. trades at 15.5x, making it the more attractively priced of the two.
This comparison is algorithmically generated and is not financial advice.
| Metric | EXEL | HRMY |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 6.5/10 | 7.5/10▲ |
| Rating | Consider Buy | Strong Buy▲ |
| Price | $58.35 | $42.06 |
| P/E Ratio | 21.0 | 15.5▲ |
| ROE | 34.8%▲ | 18.6% |
| Market Cap | $16B | $2B |
| Fair Value | $61.56 | — |
| Dividend Yield | — | — |
| Sector Rank | #29 of 168 | #5 of 168▲ |
| Model Verdicts | ||
| Piotroski | Strong▲ | Attractive |
| Buffett | Attractive | Attractive |
| Graham | Caution | Neutral▲ |
| Lynch | Attractive | Strong▲ |
| Greenblatt | Limited Data | Strong▲ |
Related comparisons
EXEL vs HRMY: Which Stock Scores Higher?
EXELIXIS, INC. (EXEL) and Harmony Biosciences Holdings, Inc. (HRMY) are both in the Health Care sector. HRMY currently leads with a composite score of 7.5/10 (Strong Buy) compared to EXEL's 6.5/10 (Consider Buy).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer